Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases
- PMID: 8632057
- DOI: 10.1016/0165-5728(95)00164-6
Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases
Abstract
The mechanism(s) of action responsible for the anti-inflammatory effects mediated by interferon (IFN)-beta are still elusive although suggestions include anti-viral effects, the enhancement of natural killer (NK) or suppressor T cell activity and opposition to the effects of inflammatory cytokines. As vascular endothelial cells are active participants in inflammatory and demyelinating processes, we decided to examine the effects of IFN-beta on the expression of major histocompatibility complex (MHC) gene products and intercellular adhesion molecule (ICAM)-1 on human vascular endothelial cells (ECs). Human umbilical ECs demonstrated constitutive expression of ICAM-1 and MHC class I molecules but did not express MHC class II molecules. Basal expression of ICAM-1 molecules was enhanced by TNF alpha and to a lesser extent by IFN-beta, but was not affected by IFN-gamma. MHC class I expression on ECs was enhanced by IFN-beta, IFN-gamma, and tumor necrosis factor (TNF)-alpha. Furthermore, a synergistic effect was observed to combinations of these interacting cytokines. Incubation of ECs with IFN-gamma, but not IFN-beta, induced class II expression in a dose dependent manner. Moreover, co-incubation of ECs with IFN-beta and IFN-gamma resulted in significant down-regulation of class II molecules expression which was directly dependent on IFN-beta concentration. Northern blot analysis of DR alpha and Beta 2-microglobulin mRNA expression suggested that cytokine-mediated regulation of MHC molecules is at the transcriptional level, while modulation of ICAM-1 expression appears to be at the transcriptional as well as post-transcriptional level. Thus, our study demonstrated that IFN-beta and interacting cytokines exert complex immunoregulatory effects on endothelial cells with differential modulatory effects on various cell surface markers. Understanding the biological significance of these immunomodulatory effects mediated by IFN-beta may have important implications for cytokine-based strategies in the treatment of inflammatory and autoimmune diseases.
Similar articles
-
Studies of the modulation of MHC antigen and cell adhesion molecule expression on human dermal microvascular endothelial cells.J Invest Dermatol. 1991 Aug;97(2):190-6. doi: 10.1111/1523-1747.ep12479643. J Invest Dermatol. 1991. PMID: 1906507
-
Interferon-beta and -gamma, but not tumor necrosis factor-alpha, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus.Cancer. 1997 Mar 1;79(5):924-34. doi: 10.1002/(sici)1097-0142(19970301)79:5<924::aid-cncr9>3.0.co;2-b. Cancer. 1997. PMID: 9041155
-
Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells.Int J Cancer. 1989 Sep 15;44(3):554-9. doi: 10.1002/ijc.2910440330. Int J Cancer. 1989. PMID: 2506138
-
Immune modulation by flaviviruses.Adv Virus Res. 2003;60:121-55. doi: 10.1016/s0065-3527(03)60004-7. Adv Virus Res. 2003. PMID: 14689693 Review.
-
Inhibition of IFN-gamma as a method of treatment of various autoimmune diseases, including skin diseases.Ernst Schering Res Found Workshop. 2006;(56):1-27. doi: 10.1007/3-540-37673-9_1. Ernst Schering Res Found Workshop. 2006. PMID: 16329644 Review.
Cited by
-
Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects.Immunology. 2007 Dec;122(4):562-70. doi: 10.1111/j.1365-2567.2007.02672.x. Epub 2007 Jul 20. Immunology. 2007. PMID: 17645499 Free PMC article.
-
Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.Drugs. 2001;61(12):1693-703. doi: 10.2165/00003495-200161120-00001. Drugs. 2001. PMID: 11693459 Review.
-
Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.J Endocrinol Invest. 1998 Dec;21(11):748-52. doi: 10.1007/BF03348040. J Endocrinol Invest. 1998. PMID: 9972674
-
What do we know about the mechanism of action of disease-modifying treatments in MS?J Neurol. 2004 Sep;251 Suppl 5:v12-v29. doi: 10.1007/s00415-004-1504-y. J Neurol. 2004. PMID: 15549350 Review.
-
Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use?CNS Drugs. 2004;18(15):1057-70. doi: 10.2165/00023210-200418150-00002. CNS Drugs. 2004. PMID: 15581378 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous